Why I Bought Titan Biotech — and Why It’s Up ~650% in 3 Years
Why I Bought Hazoor Multiprojects — and Why It Multiplied ~10×
July 26, 2026
Titan Biotech Ltd
On 4 August 2023 I told the public — right there on Facebook — that the latest stock I had just bought was Titan Biotech Ltd (BSE: 524717). You can see that post above: 1,800+ reactions, in real time, three years ago to the day. Since then Titan Biotech has been a genuine multibagger — up roughly 650%, about seven-and-a-half times, from the mid-₹50s to over ₹410 today. Here is why I bought an obscure biological-products maker that almost nobody was talking about.
A niche supplier to the health-and-nutrition boom
Titan Biotech, incorporated back in 1992, is a quiet, cGMP- and ISO-certified manufacturer and exporter of biological products — peptones, culture media, gelatin, amino acids, yeast and plant extracts and other fermentation-based inputs. These are the unglamorous raw materials that pharmaceutical, nutraceutical, food & beverage, cosmetic, veterinary and agriculture companies must buy to make their own products. It was small, under-followed and boring — and it sat right underneath some of the fastest-growing demand in the country.
The fundamental strengths that made me buy
- A picks-and-shovels business. Titan doesn’t gamble on one drug or one product — it sells the essential inputs (peptones, media, gelatin, amino acids) that dozens of pharma, nutraceutical and food makers need. You profit from a whole industry’s growth, not a single bet.
- A genuine export franchise. cGMP- and ISO-certified manufacturing supplying customers across the world — demand diversified well beyond any single market.
- High returns on capital. A return on capital employed in the mid-20s% — the signature of a quality small business, not a speculative story stock.
- A structural tailwind. Global growth in pharma, nutraceuticals, protein and collagen, and clean-label food all pull directly on the fermentation-based ingredients Titan makes.
- A tiny, ignored base. In 2023 this was an overlooked micro-cap with quietly rising profits — exactly the sort of long runway that pays off spectacularly if the market ever wakes up. It did.
Why a small ingredients maker can go up 7×
The mechanics are simple. A profitable, cash-generative niche supplier that the market has priced as a forgotten micro-cap gets re-rated hard once its earnings start compounding and investors finally notice. Titan’s profits have grown fast — a recent quarter saw net profit up roughly 94% year on year — and a low starting valuation did the rest. I’ll be candid: this is a small-cap and it moves violently (it has swung between roughly ₹82 and ₹556 in the last year alone). Bought cheap enough, on a real business with a real tailwind, that volatility worked in my favour.
Don’t take my word for it — it’s on the public record
The proof is above: my own public Facebook post from 4 August 2023, naming Titan Biotech Ltd and its BSE code 524717, seen and reacted to by more than 1,800 people at the time. No hindsight, no back-dating — a documented, time-stamped call, three years before you are reading this.
“The best small-caps are often the boring, profitable suppliers everyone else overlooks — buy the picks and shovels, not the lottery ticket.”
The lesson for you
Titan Biotech is why I hunt for cheap, profitable, cash-generating niche exporters that the market has simply forgotten to look at. It didn’t need to be a household name to be a superb investment — it needed a low price, honest earnings, and a giant industry quietly buying what it makes. Find that combination early, document it, and let time do the work.
Want to catch stocks like these before they move?
Explore how you can work with me — the same value-investing framework that found these winners, now applied for you.
Disclaimer: This article is a personal account of my own past investment decision, shared for educational purposes only. It is not a recommendation to buy or sell this or any stock at current prices. All return figures are calculated to recent market prices and adjusted for stock splits and bonuses; past performance is not a guarantee of future returns. Equity investments are subject to market risks. Please do your own research or consult your financial adviser before investing.
